TNFRSF8 and anaplastic large cell lymphoma: For example, brentuximab vedotin, the first marketed ADC drug, incorporates a peptide cleavable linker conjugated to MMAE (Figure 1), selectively binds to tumor cells expressing CD30 antigen for the treatment of relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.